Report Highlights

The US Role in the Global Epilepsy Care Supply Chain

The United States sits at the center of epilepsy innovation rather than bulk manufacturing. Branded antiseizure medicines such as UCB's Keppra and Briviact, Eisai's Fycompa and SK Life Science's Xcopri are developed and commercialized here, yet the active ingredients for most generic versions originate abroad. The country imports the bulk of its generic antiseizure API, largely from India and China, and exports high-value neuromodulation hardware and diagnostic software to Europe and Asia.

On the device side, the country is a net exporter of implantable neurostimulators and diagnostic software but a net importer of EEG hardware components. US-headquartered LivaNova and NeuroPace supply vagus nerve and responsive neurostimulation systems to hospitals worldwide, while electrode and amplifier supply chains lean on Japanese producers such as Nihon Kohden. The real vulnerability is not physical capacity but concentration: a handful of hospital networks and payers control the reimbursement flows that determine whether production volume converts into revenue.

Growth Drivers for US Epilepsy Diagnostics and Therapeutics

Demand is rising among adults over 65 as late-onset epilepsy becomes more prevalent alongside stroke and dementia. That demographic shift supports volume for levetiracetam and newer agents, pushing hospital pharmacies to expand generic antiseizure inventories and pushing community hospitals to add EEG capacity. Medicare Part D coverage sustains refill volumes through retail and mail-order channels, which keeps generic import demand steady.

Specialty cannabidiol and neuromodulation form the second and third drivers. Jazz Pharmaceuticals' Epidiolex, sourced through specialized contract manufacturing, has created a premium import-dependent API stream for pediatric Dravet and Lennox-Gastaut syndromes. Meanwhile, NeuroPace and LivaNova are expanding implant centers, which requires sterile assembly capacity, trained neurosurgical teams, and equipment orders placed with US-based suppliers.

Supply Chain Risks and Trade Barriers

Active ingredient concentration is the chain's sharpest risk. Indian and Chinese suppliers dominate generic levetiracetam, lamotrigine and topiramate inputs, and Section 301 duties on Chinese goods alongside 2025 reciprocal tariffs on Indian imports raise landed costs for generic makers already operating on thin Medicaid margins. Rupee volatility compounds the exposure, because Indian formulators price contracts in dollars while their domestic costs run in rupees.

Logistics and inspection risk add a second layer. Ocean containers arriving through the Port of Los Angeles, the Port of Long Beach and the New York and New Jersey terminals face congestion and fluctuating freight rates, while FDA warning letters and import alerts against overseas plants can halt shipments for months. Recurring shortages of injectable phenobarbital and diazepam show how a single plant failure cascades into hospital emergency protocols with no quick domestic substitute.

Trade and Investment Opportunities in US Epilepsy Care

Import substitution offers the clearest commercial opening. Generic manufacturers with existing US finished-dose sites can add API capacity for levetiracetam and lamotrigine, positioning themselves for federal procurement preferences for domestically sourced medicines. Contract manufacturers in the South Census Region, which already hosts pharmaceutical plants, can capture this demand with shorter lead times than offshore suppliers.

Inbound investment in neurodiagnostics and neuromodulation is the second opportunity. Ceribell's AI-assisted point-of-care EEG and wearable seizure-detection devices require contract assembly and cloud data infrastructure, while NeuroPace's responsive stimulation growth requires sterile manufacturing partners. Logistics hubs near Memphis and Louisville already serve medical distribution, making them practical bases for USMCA-compliant re-export of devices to Canada and Mexico.

Market at a Glance

Leading Market Participants

• UCB
• Jazz Pharmaceuticals
• Eisai
• SK Life Science
• Neurelis
• Teva Pharmaceuticals
• LivaNova
• NeuroPace
• Ceribell
• Natus Medical

Regulatory and Trade Policy Environment for US Epilepsy Care

The regulatory framework is anchored by FDA pathways: ANDA approval for generics, NDA approval for novel antiseizure drugs, and PMA or 510(k) clearance for implants and EEG systems. A Section 232 pharmaceutical investigation launched in 2025 threatens tariffs on imported finished drugs and APIs, while the US-EU framework agreement capped tariffs on EU pharmaceuticals at 15 percent. USMCA provides duty-free treatment for qualifying devices traded with Canada and Mexico, subject to rules of origin.

Reimbursement policy shapes trade flows as much as tariffs do. Medicare Part D and Medicaid best price rules determine generic and branded margins, and Inflation Reduction Act price negotiation will affect high-spend neurology products over time. Orphan designations for Dravet and Lennox-Gastaut therapies extend market exclusivity, while CMS coverage decisions for responsive neurostimulation determine implant volumes across hospital systems.

US Epilepsy Care Supply Chain Outlook to 2032

Supply chains will shift toward domestic API capacity and regional device assembly by 2032. As Indian and Chinese shares of generic inputs decline under tariff pressure, Mexican and Canadian manufacturers will gain share in device subassemblies, while US generic makers concentrate on high-volume molecules such as levetiracetam where scale justifies onshore plants.

Technology will alter comparative advantage. AI-assisted EEG interpretation, cloud-based long-term monitoring and closed-loop neurostimulators will make software and data services a larger share of value than hardware, favoring US developers over Japanese and European hardware exporters. Hospitals adopting point-of-care monitoring will reduce EMU bed demand, redistributing diagnostic volume toward community facilities and ambulatory settings by the early 2030s.